2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.

Novel 2,6,9-substituted purine derivatives represent a class of potent and selective inhibitors of CDK1/cyclinB. The synthesis, SAR and biological profile of selected compounds are described.

[1]  L. Cornelius,et al.  Facile Preparation of 2,6-Disubstituted Purines Using Solid-Phase Chemistry. , 1997, The Journal of organic chemistry.

[2]  S H Kim,et al.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Meijer,et al.  Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. , 1997, Journal of medicinal chemistry.

[4]  Peter G. Schultz,et al.  A Structure-Based Library Approach to Kinase Inhibitors , 1996 .

[5]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[6]  D O Morgan,et al.  Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. , 1992, The EMBO journal.

[7]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[8]  C. Turck,et al.  Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit , 1993, Nature.

[9]  V. Rialet,et al.  A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates. , 1991, Anticancer research.

[10]  M. Kitagawa,et al.  Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. , 1993, Oncogene.

[11]  M. Wick,et al.  Synthesis and activity of 2,6,9-trisubstituted purines , 1997 .

[12]  L. Meijer,et al.  cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF , 1988, Cell.

[13]  Peter G. Schultz,et al.  Combinatorial synthesis of 2,9-substituted purines , 1997 .

[14]  H. Tung,et al.  Interaction between the cell-cycle-control proteins p34cdc2 and p9CKShs2. Evidence for two cooperative binding domains in p9CKShs2. , 1992, European journal of biochemistry.

[15]  J. Kjellberg,et al.  Studies on the Alkylation of Derivatives of Guanines , 1989 .

[16]  R. A. Swank,et al.  Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. , 1992, Biochemical and biophysical research communications.

[17]  P. Russell,et al.  Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe. , 1990, Genes & development.

[18]  D. Morgan,et al.  Activation of human cyclin-dependent kinases in vitro. , 1992, Molecular biology of the cell.

[19]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[20]  U. Regenass,et al.  Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. , 1992, Cancer research.

[21]  J. Newport,et al.  Evidence that the G1-S and G2-M transitions are controlled by different cdc2 proteins in higher eukaryotes , 1991, Cell.

[22]  E. Sausville,et al.  Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.

[23]  C. Abell,et al.  Solution-phase synthesis of 2,6,9-trisubstituted purines , 1998 .

[24]  L. Meijer,et al.  Cyclin is a component of the sea urchin egg M‐phase specific histone H1 kinase. , 1989, The EMBO journal.

[25]  L Meijer,et al.  Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. , 1998, Bioorganic & medicinal chemistry letters.